TY - JOUR AB - Benign prostate hypertrophy (BPH) and prostate cancer (PC) are prostate chronic diseases that require a long period for development from a small lesion to clinical manifestation. PC is the most common cancer in men in Europe and the Americas. Tumor growth and metastasis depend upon the development of neovasculature around the tumor. This process, called angiogenesis, may be regulated by NO, and thus modulation of NO production could play an important role in tumor progression. Recent studies report the involvement of DDAH, an enzyme which metabolizes the endogenous NOS inhibitor ADMA, in the development of tumor vasculature. The aim of the present study was to verify the involvement of the DDAH/NOS pathway in the progression of prostate cancer. The effect of the NOS inhibitor L-NAME was evaluated in the human prostate cancer cell line LnCap and in BPH-1 cells which represent benign prostatic hypertrophy. Higher DDAH-2, eNOS, iNOS and VEGF expression was found in LnCap cells compared to BPH-1 cells. L-NAME treatment of LnCap cells resulted in a reduction in VEGF, iNOS and eNOS expression. VEGF, iNOS and eNOS inhibition is a promising approach for targeting tumor vasculature and certain NOS inhibitors could potentially serve as experimental agents for treatment of certain chemoresistant tumors, including prostate tumors. Moreover, since in our experimental conditions L-NAME was unable to reduce DDAH activity and expression, it is plausible to hypothesize the development of a targeted polypharmacological approach by developing dual and specific inhibitors of DDAH and NOS to better control NO biosynthesis. AD - Dipartimento di Scienze del Farmaco, Sezione di Biochimica, Università di Catania, I-95125 Catania, Italy null Dipartimento di Scienze del Farmaco, Sezione di Biochimica, Università di Catania, v.le A. Doria 6, I-95125 Catania, Italy AU - Vanella,Luca AU - Di Giacomo,Claudia AU - Acquaviva,Rosaria AU - Santangelo,Rosa AU - Cardile,Venera AU - Barbagallo,Ignazio AU - Abraham,Nader ,G. AU - Sorrenti,Valeria DA - 2011/11/01 DO - 10.3892/ijo.2011.1107 EP - 1310 IS - 5 JO - Int J Oncol KW - DDAH NOS VEGF L-NAME angiogenesis prostate cancer PY - 2011 SN - 1019-6439 1791-2423 SP - 1303 ST - The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME T2 - International Journal of Oncology TI - The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME UR - https://doi.org/10.3892/ijo.2011.1107 VL - 39 ER -